Astrazenca reveals positive results from Phase III trial of Lynparza
Category: #health  By Paroma Bhattacharya  Date: 2019-08-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Astrazenca reveals positive results from Phase III trial of Lynparza

Lynparza is a PARP inhibitor with promising Phase III results in ovarian breast pancreatic and prostate cancers.

AstraZeneca plc a biopharmaceutical company and MSD Inc. (also known as Merck & Co. Inc. inside Canada and the U.S.) have recently announced positive results from the Phase III PROfound trial of Lynparza in men who suffer from metastatic castration-resistant prostate cancer (mCRPC) with a HRRm (homologous recombination repair gene mutation) and have progressed with prior treatment with new hormonal anticancer therapeutics like abiraterone and enzalutamide.

According to reliable reports the trial’s outcome showed a clinically meaningful and statistically-significant development in the primary endpoint of radiographic progression-free survival (rPFS) with Lynparza vs. abiraterone or enzalutamide in men with mCRPC chosen for BRCA1/2 or ATM gene mutations, a subtype of HRR gene mutations. The tolerability and safety profile of Lynparza was also normally steady with previous trials.

Speaking on the move, Jose Baselga Executive Vice President, Oncology R&D, said that for men suffering from metastatic castration-resistant prostate cancer the disease is still deadly mainly for ones who have failed on a new hormonal anticancer treatment.

He added; the PROfound trial shows the promising value of genomic testing in at-risk patient population and the company is looking forward to discussing these results with international health authorities soon.

Roy Baynes, Chief Medical Officer, MSD Research Laboratories, and Head and Senior Vice President of Global Clinical Development said that Metastatic castration-resistant prostate cancer remains a fatal disease and an area of extensive needed medical attention. He claims that the PROfound Phase III trial is an example of AstraZeneca and MSD’s shared promise to develop long-term results for people suffering from cancer.

As per reports, AstraZeneca and MSD are planning to reveal the full data from their trial at an upcoming medical meeting. Currently the organizations are seeking other trials in prostate cancer, which includes the Phase III PROpel trial and piloting Lynparza as a first-line therapy in mCRPC in combined with abiraterone.

Source Credit: https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2019/lynparza-phase-iii-profound-trial-in-hrr-mutation-selected-metastatic-castration-resistant-prostate-cancer-met-primary-endpoint-07082019.html



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Bio-Thera Solutions commences Phase 1 study for Simponi® biosimilar
Bio-Thera Solutions commences Phase 1 study for Simponi® biosimilar
By Paroma Bhattacharya

Bio-Thera Solutions, a China based pharmaceutical company, has reportedly announced the start of dosing of its first batch of healthy volunteers in order to compare the safety and pharmacokinetics of BAT2506, proposed ...

Mevion & C-RAD integrate for better treatment in proton therapy
Mevion & C-RAD integrate for better treatment in proton therapy
By Paroma Bhattacharya

  • C-RAD to offer a specific version of Catalyst System named Catalyst PT in proton therapy.
  • Catalyst PT would be especially used for thoracic tumor i...

Amazon plans to open a brick-and-mortar liquor store in San Francisco
Amazon plans to open a brick-and-mortar liquor store in San Francisco
By Paroma Bhattacharya

  • The company is looking to launch a liquor shop in San Francisco for various alcoholic beverages.
     
  • Application for a liquor license and...